Solid lipid nanoparticle formulations of docetaxel prepared with high melting point triglycerides: In vitro and in vivo evaluation

Molecular Pharmaceutics

Volumn 11, Issue 4, 2014, Pages 1239-1249

  Naguib, Youssef Wahib ^a   Rodriguez, B Leticia ^a   Li, Xinran ^a   Hursting, Stephen D ^b   Williams, Robert O ^a   Cui, Zhengrong ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b The University of Texas at Austin   (United States)

Author keywords

antitumor efficacy; biodistribution; caspase 3; cytotoxicity; in vitro release; SLNs

Indexed keywords

DOCETAXEL; POLYSORBATE 80; SOLID LIPID NANOPARTICLE; TRIACYLGLYCEROL; TRIPALMITIN; TRISTEARIN; ANTINEOPLASTIC AGENT; NANOPARTICLE; TAXOID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG CYTOTOXICITY; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; FEMALE; GEL PERMEATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IC 50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MELTING POINT; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY; TUMOR VOLUME; X RAY DIFFRACTION; ZETA POTENTIAL; ANIMAL; C57BL MOUSE; CHEMISTRY; MEDICINAL CHEMISTRY; TISSUE DISTRIBUTION; TRANSITION TEMPERATURE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; FEMALE; MICE; MICE, INBRED C57BL; NANOPARTICLES; TAXOIDS; TISSUE DISTRIBUTION; TRANSITION TEMPERATURE; TRIGLYCERIDES;

EID: 84897973310     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp4006968     Document Type: Article

References (62)

1. Zhao, P.; Astruc, D. Docetaxel nanotechnology in anticancer therapy ChemMedChem 2012, 7 (6) 952-972
2. Cortes, J. E.; Pazdur, R. Docetaxel J. Clin. Oncol. 1995, 13 (10) 2643-2655
3. Herbst, R. S.; Khuri, F. R. Mode of action of docetaxel-a basis for combination with novel anticancer agents Cancer Treat. Rev. 2003, 29 (5) 407-415
4. Engels, F. K.; Mathot, R. A.; Verweij, J. Alternative drug formulations of docetaxel: a review Anticancer Drugs 2007, 18 (2) 95-103
5. Tan, Q.; Liu, X.; Fu, X.; Li, Q.; Dou, J.; Zhai, G. Current development in nanoformulations of docetaxel Expert Opin. Drug Delivery 2012, 9 (8) 975-990
6. Seo, Y. G.; Kim, D. W.; Yeo, W. H.; Ramasamy, T.; Oh, Y. K.; Park, Y. J.; Kim, J. A.; Oh, D. H.; Ku, S. K.; Kim, J. K.; Yong, C. S.; Kim, J. O.; Choi, H. G. Docetaxel-loaded thermosensitive and bioadhesive nanomicelles as a rectal drug delivery system for enhanced chemotherapeutic effect Pharm. Res. 2013, 30 (7) 1860-1870
7. ten Tije, A. J.; Verweij, J.; Loos, W. J.; Sparreboom, A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy Clin. Pharmacokinet. 2003, 42 (7) 665-685
8. Hennenfent, K. L.; Govindan, R. Novel formulations of taxanes: a review. Old wine in a new bottle? Ann. Oncol. 2006, 17 (5) 735-749
9. Brannon-Peppas, L.; Blanchette, J. O. Nanoparticle and targeted systems for cancer therapy Adv. Drug Delivery Rev. 2004, 56 (11) 1649-1659
10. Alexis, F.; Rhee, J. W.; Richie, J. P.; Radovic-Moreno, A. F.; Langer, R.; Farokhzad, O. C. New frontiers in nanotechnology for cancer treatment Urol. Oncol. 2008, 26 (1) 74-85
11. Yoo, J. W.; Doshi, N.; Mitragotri, S. Adaptive micro and nanoparticles: temporal control over carrier properties to facilitate drug delivery Adv. Drug Delivery Rev. 2011, 63 (14-15) 1247-1256
12. Elsabahy, M.; Wooley, K. L. Design of polymeric nanoparticles for biomedical delivery applications Chem. Soc. Rev. 2012, 41 (7) 2545-2561
13. Nie, S.; Xing, Y.; Kim, G. J.; Simons, J. W. Nanotechnology applications in cancer Annu. Rev. Biomed. Eng. 2007, 9, 257-288
14. Koo, H.; Huh, M. S.; Sun, I. C.; Yuk, S. H.; Choi, K.; Kim, K.; Kwon, I. C. In vivo targeted delivery of nanoparticles for theranosis Acc. Chem. Res. 2011, 44 (10) 1018-1028
15. Petros, R. A.; DeSimone, J. M. Strategies in the design of nanoparticles for therapeutic applications Nat. Rev. Drug Discovery 2010, 9 (8) 615-627
16. Byrne, J. D.; Betancourt, T.; Brannon-Peppas, L. Active targeting schemes for nanoparticle systems in cancer therapeutics Adv. Drug Delivery Rev. 2008, 60 (15) 1615-1626
17. Fang, J.; Nakamura, H.; Maeda, H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect Adv. Drug Delivery Rev. 2011, 63 (3) 136-151
18. Prabhakar, U.; Maeda, H.; Jain, R. K.; Sevick-Muraca, E. M.; Zamboni, W.; Farokhzad, O. C.; Barry, S. T.; Gabizon, A.; Grodzinski, P.; Blakey, D. C. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology Cancer Res. 2013, 73 (8) 2412-2417
19. Feng, L.; Mumper, R. J. A critical review of lipid-based nanoparticles for taxane delivery Cancer Lett. 2013, 334 (2) 157-175
20. Betancourt, T.; Byrne, J. D.; Sunaryo, N.; Crowder, S. W.; Kadapakkam, M.; Patel, S.; Casciato, S.; Brannon-Peppas, L. PEGylation strategies for active targeting of PLA/PLGA nanoparticles J. Biomed. Mater. Res. A 2009, 91 (1) 263-276
21. Jokerst, J. V.; Lobovkina, T.; Zare, R. N.; Gambhir, S. S. Nanoparticle PEGylation for imaging and therapy Nanomedicine (London) 2011, 6 (4) 715-728
22. Muller, R. H.; Mader, K.; Gohla, S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art Eur. J. Pharm. Biopharm. 2000, 50 (1) 161-177
23. Venkateswarlu, V.; Manjunath, K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles J. Controlled Release 2004, 95 (3) 627-638
24. Yang, S. C.; Lu, L. F.; Cai, Y.; Zhu, J. B.; Liang, B. W.; Yang, C. Z. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain J. Controlled Release 1999, 59 (3) 299-307
25. Schwarz, C.; Mehnert, W.; Lucks, J. S.; Mller, R. H. Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization J. Controlled Release 1994, 30 (1) 83-96
26. Mehnert, W.; Mader, K. Solid lipid nanoparticles: production, characterization and applications Adv. Drug Delivery Rev. 2001, 47 (2-3) 165-196
27. Xu, Z.; Chen, L.; Gu, W.; Gao, Y.; Lin, L.; Zhang, Z.; Xi, Y.; Li, Y. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma Biomaterials 2009, 30 (2) 226-232
28. Gao, Y.; Yang, R.; Zhang, Z.; Chen, L.; Sun, Z.; Li, Y. Solid lipid nanoparticles reduce systemic toxicity of docetaxel: performance and mechanism in animal Nanotoxicology 2011, 5 (4) 636-649
29. Xu, W.; Lim, S. J.; Lee, M. K. Cellular uptake and antitumour activity of paclitaxel incorporated into trilaurin-based solid lipid nanoparticles in ovarian cancer J. Microencapsulation 2013, 30 (8) 755-761
30. Lee, M. K.; Lim, S. J.; Kim, C. K. Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles Biomaterials 2007, 28 (12) 2137-2146
31. Heurtault, B.; Saulnier, P.; Pech, B.; Proust, J. E.; Benoit, J. P. A novel phase inversion-based process for the preparation of lipid nanocarriers Pharm. Res. 2002, 19 (6) 875-880
32. Peltier, S.; Oger, J. M.; Lagarce, F.; Couet, W.; Benoit, J. P. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules Pharm. Res. 2006, 23 (6) 1243-1250
33. Lacoeuille, F.; Hindre, F.; Moal, F.; Roux, J.; Passirani, C.; Couturier, O.; Cales, P.; Le Jeune, J. J.; Lamprecht, A.; Benoit, J. P. In vivo evaluation of lipid nanocapsules as a promising colloidal carrier for paclitaxel Int. J. Pharm. 2007, 344 (1-2) 143-149
34. Li, R.; Eun, J. S.; Lee, M. K. Pharmacokinetics and biodistribution of paclitaxel loaded in pegylated solid lipid nanoparticles after intravenous administration Arch. Pharm. Res. 2011, 34 (2) 331-337
35. Videira, M. A.; Arranja, A. G.; Gouveia, L. F. Experimental design towards an optimal lipid nanosystem: a new opportunity for paclitaxel-based therapeutics Eur. J. Pharm. Sci. 2013, 49 (2) 302-310
36. Huynh, L.; Grant, J.; Leroux, J. C.; Delmas, P.; Allen, C. Predicting the solubility of the anti-cancer agent docetaxel in small molecule excipients using computational methods Pharm. Res. 2008, 25 (1) 147-157
37. Chan, J. M.; Zhang, L.; Yuet, K. P.; Liao, G.; Rhee, J. W.; Langer, R.; Farokhzad, O. C. PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery Biomaterials 2009, 30 (8) 1627-1634
38. Zhu, S.; Lansakara, P.; Li, X.; Cui, Z. Lysosomal Delivery of a Lipophilic Gemcitabine Prodrug Using Novel Acid-Sensitive Micelles Improved Its Antitumor Activity Bioconjugate Chem. 2012, 23 (5) 966-980
39. Yanasarn, N.; Sloat, B. R.; Cui, Z. Nanoparticles engineered from lecithin-in-water emulsions as a potential delivery system for docetaxel Int. J. Pharm. 2009, 379 (1) 174-180
40. Tao, W.; Zeng, X.; Liu, T.; Wang, Z.; Xiong, Q.; Ouyang, C.; Huang, L.; Mei, L. Docetaxel-loaded nanoparticles based on star-shaped mannitol-core PLGA-TPGS diblock copolymer for breast cancer therapy Acta Biomater. 2013, 9 (11) 8910-8920
41. Sloat, B. R.; Sandoval, M. A.; Li, D.; Chung, W. G.; Lansakara, P.; Proteau, P. J.; Kiguchi, K.; DiGiovanni, J.; Cui, Z. In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles Int. J. Pharm. 2011, 409 (1-2) 278-288
42. Kim, D. W.; Kim, S. Y.; Kim, H. K.; Kim, S. W.; Shin, S. W.; Kim, J. S.; Park, K.; Lee, M. Y.; Heo, D. S. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer Ann. Oncol. 2007, 18 (12) 2009-2014
43. Lee, K. S.; Chung, H. C.; Im, S. A.; Park, Y. H.; Kim, C. S.; Kim, S. B.; Rha, S. Y.; Lee, M. Y.; Ro, J. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer Breast Cancer Res. Treat. 2008, 108 (2) 241-250
44. Shi, J.; Xiao, Z.; Kamaly, N.; Farokhzad, O. C. Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation Acc. Chem. Res. 2011, 44 (10) 1123-1134
45. Mikhail, A. S.; Allen, C. Poly(ethylene glycol)-b-poly(epsilon- caprolactone) micelles containing chemically conjugated and physically entrapped docetaxel: synthesis, characterization, and the influence of the drug on micelle morphology Biomacromolecules 2010, 11 (5) 1273-1280
46. Farokhzad, O. C.; Langer, R. Impact of nanotechnology on drug delivery ACS Nano 2009, 3 (1) 16-20
47. Torchilin, V. Tumor delivery of macromolecular drugs based on the EPR effect Adv. Drug Delivery Rev. 2011, 63 (3) 131-135
48. Iyer, A. K.; Khaled, G.; Fang, J.; Maeda, H. Exploiting the enhanced permeability and retention effect for tumor targeting Drug Discovery Today 2006, 11 (17-18) 812-818
49. Maeda, H.; Bharate, G. Y.; Daruwalla, J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect Eur. J. Pharm. Biopharm. 2009, 71 (3) 409-419
50. Kraus, L. A.; Samuel, S. K.; Schmid, S. M.; Dykes, D. J.; Waud, W. R.; Bissery, M. C. The mechanism of action of docetaxel (Taxotere) in xenograft models is not limited to bcl-2 phosphorylation Invest. New Drugs 2003, 21 (3) 259-268
51. Fang, J.; Sawa, T.; Maeda, H. Factors and mechanism of "EPR: effect and the enhanced antitumor effects of macromolecular drugs including SMANCS Adv. Exp. Med. Biol. 2003, 519, 29-49
52. Wang, L.; Li, M.; Zhang, N. Folate-targeted docetaxel-lipid-based- nanosuspensions for active-targeted cancer therapy Int. J. Nanomed. 2012, 7, 3281-3294
53. Liu, D.; Liu, F.; Liu, Z.; Wang, L.; Zhang, N. Tumor specific delivery and therapy by double-targeted nanostructured lipid carriers with anti-VEGFR-2 antibody Mol. Pharmaceutics 2011, 8 (6) 2291-2301
54. Liu, D.; Liu, Z.; Wang, L.; Zhang, C.; Zhang, N. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel Colloids Surf., B 2011, 85 (2) 262-269
55. Mi, Y.; Zhao, J.; Feng, S. S. Targeted co-delivery of docetaxel, cisplatin and herceptin by vitamin E TPGS-cisplatin prodrug nanoparticles for multimodality treatment of cancer J. Controlled Release 2013, 169 (3) 185-192
56. Westesen, K.; Bunjes, H. Do nanoparticles prepared from lipids solid at room temperature always possess a solid lipid matrix? Int. J. Pharm. 1995, 115 (1) 129-131
57. Yerlikaya, F.; Ozgen, A.; Vural, I.; Guven, O.; Karaagaoglu, E.; Khan, M. A.; Capan, Y. Development and Evaluation of Paclitaxel Nanoparticles Using a Quality-by-Design Approach J. Pharm. Sci. 2013, 102 (10) 3748-3761
58. Bunjes, H.; Westesen, K.; Koch, M. H. J. Crystallization tendency and polymorphic transitions in triglyceride nanoparticles Int. J. Pharm. 1996, 129 (1-2) 159-173
59. Wasutrasawat, P.; Al-Obaidi, H.; Gaisford, S.; Lawrence, M. J.; Warisnoicharoen, W. Drug solubilisation in lipid nanoparticles containing high melting point triglycerides Eur. J. Pharm. Biopharm. 2013, 85 (3) 365-371
60. Mosallaei, N.; Jaafari, M. R.; Hanafi-Bojd, M. Y.; Golmohammadzadeh, S.; Malaekeh-Nikouei, B. Docetaxel-loaded solid lipid nanoparticles: preparation, characterization, in vitro, and in vivo evaluations J. Pharm. Sci. 2013, 102 (6) 1994-2004
61. Li, X.; Wang, D.; Zhang, J.; Pan, W. Preparation and pharmacokinetics of docetaxel based on nanostructured lipid carriers J. Pharm. Pharmacol. 2009, 61 (11) 1485-1492
62. Wang, S.; Koo, S. I. Plasma clearance and hepatic utilization of stearic, myristic and linoleic acids introduced via chylomicrons in rats Lipids 1993, 28 (8) 697-703